AKT1 and cancer: In addition, FIS controls the cell cycle and inhibits cyclin-dependent kinases (CDKs) in human cancer cell lines, modulates the pathways of lipid and protein kinases activated by AMP, and affects various signaling pathways, for example, by inhibition of PI3K/Akt/mTOR signaling [20], mitogen-activated protein kinases (MAPK) [21], and nuclear transcription factor (NF-κB) [22].